Canavan disease: Difference between revisions

Jump to navigation Jump to search
Line 56: Line 56:
*The [[prevalence]] of Canavan Disease is approximately 1 per 100,000 individuals in general population.<ref name="ReddyCalloni2018">{{cite journal|last1=Reddy|first1=Nihaal|last2=Calloni|first2=Sonia F.|last3=Vernon|first3=Hilary J.|last4=Boltshauser|first4=Eugen|last5=Huisman|first5=Thierry A. G. M.|last6=Soares|first6=Bruno P.|title=Neuroimaging Findings of Organic Acidemias and Aminoacidopathies|journal=RadioGraphics|volume=38|issue=3|year=2018|pages=912–931|issn=0271-5333|doi=10.1148/rg.2018170042}}</ref>
*The [[prevalence]] of Canavan Disease is approximately 1 per 100,000 individuals in general population.<ref name="ReddyCalloni2018">{{cite journal|last1=Reddy|first1=Nihaal|last2=Calloni|first2=Sonia F.|last3=Vernon|first3=Hilary J.|last4=Boltshauser|first4=Eugen|last5=Huisman|first5=Thierry A. G. M.|last6=Soares|first6=Bruno P.|title=Neuroimaging Findings of Organic Acidemias and Aminoacidopathies|journal=RadioGraphics|volume=38|issue=3|year=2018|pages=912–931|issn=0271-5333|doi=10.1148/rg.2018170042}}</ref>
*Canavan disease usually affects individuals of the [[Eastern European]] ([[Ashkenazi]]) [[Jewish]] [[ancestry]].  
*Canavan disease usually affects individuals of the [[Eastern European]] ([[Ashkenazi]]) [[Jewish]] [[ancestry]].  
*In [[Ashkenazi Jews]] the [[prevalence]] of this disease is 1 in 6000-14000. 1 in 37-57 individuals are [[carriers]] among this population.
*In [[Ashkenazi Jews]] the [[prevalence]] of this disease is 1 in 6000-14000. 1 in 37-57 individuals are [[carriers]] among this population.<ref name="Zayed2015">{{cite journal|last1=Zayed|first1=Hatem|title=Canavan disease: An Arab scenario|journal=Gene|volume=560|issue=1|year=2015|pages=9–14|issn=03781119|doi=10.1016/j.gene.2015.02.009}}</ref>
<ref name="Zayed2015">{{cite journal|last1=Zayed|first1=Hatem|title=Canavan disease: An Arab scenario|journal=Gene|volume=560|issue=1|year=2015|pages=9–14|issn=03781119|doi=10.1016/j.gene.2015.02.009}}</ref>


==Risk Factors==
==Risk Factors==

Revision as of 18:02, 7 August 2020

WikiDoc Resources for Canavan disease

Articles

Most recent articles on Canavan disease

Most cited articles on Canavan disease

Review articles on Canavan disease

Articles on Canavan disease in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Canavan disease

Images of Canavan disease

Photos of Canavan disease

Podcasts & MP3s on Canavan disease

Videos on Canavan disease

Evidence Based Medicine

Cochrane Collaboration on Canavan disease

Bandolier on Canavan disease

TRIP on Canavan disease

Clinical Trials

Ongoing Trials on Canavan disease at Clinical Trials.gov

Trial results on Canavan disease

Clinical Trials on Canavan disease at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Canavan disease

NICE Guidance on Canavan disease

NHS PRODIGY Guidance

FDA on Canavan disease

CDC on Canavan disease

Books

Books on Canavan disease

News

Canavan disease in the news

Be alerted to news on Canavan disease

News trends on Canavan disease

Commentary

Blogs on Canavan disease

Definitions

Definitions of Canavan disease

Patient Resources / Community

Patient resources on Canavan disease

Discussion groups on Canavan disease

Patient Handouts on Canavan disease

Directions to Hospitals Treating Canavan disease

Risk calculators and risk factors for Canavan disease

Healthcare Provider Resources

Symptoms of Canavan disease

Causes & Risk Factors for Canavan disease

Diagnostic studies for Canavan disease

Treatment of Canavan disease

Continuing Medical Education (CME)

CME Programs on Canavan disease

International

Canavan disease en Espanol

Canavan disease en Francais

Business

Canavan disease in the Marketplace

Patents on Canavan disease

Experimental / Informatics

List of terms related to Canavan disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Zehra Malik, M.B.B.S[2]


Synonyms and keywords:

For patient information, click here

Canavan disease
ICD-9 330.0
OMIM 271900
DiseasesDB 29780
MedlinePlus 001586

Overview

Historical Perspective

  • Canavan disease was first described in 1931 by an American neuropathologist, Myrtelle Canavan.[1]
  • She wrote a case-study in 1931 of a child who died at sixteen-month of age and was found to have cerebral spongy degenerative changes of the central nervous system.[1]
  • The disease was later named after Myrtelle Canavan.

Classification

  • There is no established system for the classification of Canavan disease.
  • Canavan disease is categorized as a leukodystrophy.[2]

Pathophysiology

Causes

Differentiating Canavan disease from Other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

  • Most commonly patients usually present at three to six months of age with lethargy, weak cry, poor head control, macrocephaly, blindness, hypotonia, poor feeding due to dysfunctional swallowing, seizures, and/or irritability.[7]
  • The most common form of the disease is also the most serious form and progresses rapidly.
  • The late-onset variant of the disease has mild and non-specific signs and symptoms including speech delay and motor skill delay. It usually presents after 5 years of age.

Physical Examination

Laboratory Findings

Electrocardiogram

  • There are no ECG findings associated with Canavan disease.

X-ray

  • There are no x-ray findings associated with Canavan disease.

Echocardiography or Ultrasound

  • There are no echocardiography/ultrasound findings associated with Canavan disease.

CT scan

MRI

Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

See also

External links

References

  1. 1.0 1.1 Canavan, Myrtelle M. (1931). "SCHILDER'S ENCEPHALITIS PERIAXIALIS DIFFUSA". Archives of Neurology & Psychiatry. 25 (2): 299. doi:10.1001/archneurpsyc.1931.02230020085005. ISSN 0096-6754.
  2. Froukh, Tawfiq (2019). "First Record Mutations in the Genes ASPA and ARSA Causing Leukodystrophy in Jordan". BioMed Research International. 2019: 1–7. doi:10.1155/2019/7235914. ISSN 2314-6133.
  3. 3.0 3.1 3.2 Matalon, R.; Michals, K.; Sebesta, D.; Deanching, M.; Gashkoff, P.; Casanova, J.; Optiz, John M.; Reynolds, James F. (1988). "Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with canavan disease". American Journal of Medical Genetics. 29 (2): 463–471. doi:10.1002/ajmg.1320290234. ISSN 0148-7299.
  4. von Jonquieres, Georg; Spencer, Ziggy H. T.; Rowlands, Benjamin D.; Klugmann, Claudia B.; Bongers, Andre; Harasta, Anne E.; Parley, Kristina E.; Cederholm, Jennie; Teahan, Orla; Pickford, Russell; Delerue, Fabien; Ittner, Lars M.; Fröhlich, Dominik; McLean, Catriona A.; Don, Anthony S.; Schneider, Miriam; Housley, Gary D.; Rae, Caroline D.; Klugmann, Matthias (2017). "Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy". Acta Neuropathologica. 135 (1): 95–113. doi:10.1007/s00401-017-1784-9. ISSN 0001-6322.
  5. 5.0 5.1 Reddy, Nihaal; Calloni, Sonia F.; Vernon, Hilary J.; Boltshauser, Eugen; Huisman, Thierry A. G. M.; Soares, Bruno P. (2018). "Neuroimaging Findings of Organic Acidemias and Aminoacidopathies". RadioGraphics. 38 (3): 912–931. doi:10.1148/rg.2018170042. ISSN 0271-5333.
  6. Zayed, Hatem (2015). "Canavan disease: An Arab scenario". Gene. 560 (1): 9–14. doi:10.1016/j.gene.2015.02.009. ISSN 0378-1119.
  7. Traeger, Eveline C.; Rapin, Isabelle (1998). "The Clinical Course of Canavan Disease". Pediatric Neurology. 18 (3): 207–212. doi:10.1016/S0887-8994(97)00185-9. ISSN 0887-8994.

Template:WH Template:WS